Pangali EV/EBITDA Pasithea Therapeutics Corp. (KTTA)

Pasithea Therapeutics (KTTA) develops drugs to combat severe inflammation and brain lesions, leveraging long-term patent protection. The price indicator on the chart confirms the effectiveness of this strategy, reaching a value of 0.00. Management is focusing on innovative treatment of depression via the immune system, while a streamlined raw material supply chain ensures the uninterrupted execution of all clinical trials for CNS drugs.

For Pasithea Therapeutics (KTTA), which relies on a stable pool of neurobiologists, EV/EBITDA serves as a tool for assessing business value while accounting for all debt obligations. The EV/EBITDA trajectory of Pasithea Therapeutics reflects the ratio of total enterprise value to operating income before taxes and amortization, eliminating the impact of financing structure. Investors should interpret the dynamics of this metric as a measure of how effectively the company capitalizes its intellectual potential into real profit.